Management just needs to sell one of their assets and get on with building a formidable Biotech powerhouse. Its really a mindset change; if they have adequate funding ...then they get Uplisted and can soar to new heights.

Eventually, they can buy more assets and progress things forward. In my knowledge of biotech investing; the Scientific data is whats its all about...the question is Mgt. trying to mature assets and transact later down the road (which I think is a dangerous concept....if market conditions continue to improve it just might open up some new investor interest willing to take on more risk.

Time will tell!!